ArticleOncology letters2018
miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- LncRNA SNHG25 promotes proliferation, migration, and invasion of acute myeloid leukemia by competitively binding to miR-205-5p.Clinical and experimental medicine · 2026Article
- RNA-binding protein gene NOP58 exhibits crucial prognostic and therapeutic value in Ewing sarcoma.Hereditas · 2025Article
- MicroRNA Sequencing of Serum Exosomes Reveals miR205-5p as an Anti-Fibrogenic Factor Against Intestinal Fibrosis in Crohn's Disease.International journal of molecular sciences · 2025Article
- Tumor-exosomal miR-205-5p as a diagnostic biomarker for colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Exosome encapsulation of miR-205-5p suppresses neuroblastoma progression by targeting RUNX2.World journal of pediatric surgery · 2025Article
- Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer.Molecular biotechnology · 2024Article
- CD8Molecular medicine reports · 2024Article
- Article
- Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.International journal of molecular sciences · 2023Article
- LncRNA HOTAIR as a ceRNA is related to breast cancer risk and prognosis.Breast cancer research and treatment · 2023Article
- Circle RNA circ_0007331 promotes colorectal carcinoma by targeting miR-205-5p/high-mobility group A2 axis.Bioengineered · 2022Article
- MiR-205-5p Functions as a Tumor Suppressor in Gastric Cancer Cells through Downregulating FAM84B.Journal of oncology · 2022Article
- DNAJA1 Stabilizes EF1A1 to Promote Cell Proliferation and Metastasis of Liver Cancer Mediated by miR-205-5p.Journal of oncology · 2022Article
- MicroRNAs as Potential Biomarkers in Pituitary Adenomas.Non-coding RNA · 2021Review
- Long noncoding RNA DLEU2 drives the malignant behaviors of thyroid cancer through mediating the miR-205-5p/TNFAIP8 axis.Endocrine connections · 2021Article
- Preclinical Experimental Applications of miRNA Loaded BMSC Extracellular Vesicles.Stem cell reviews and reports · 2021Review
- Profiling of miR-205/P4HA3 Following Angiotensin II-Induced Atrial Fibrosis: Implications for Atrial Fibrillation.Frontiers in cardiovascular medicine · 2021Article
- Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.Bioscience reports · 2020Observational
- MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy.Biomolecules · 2020Review
- Coordinated AR and microRNA regulation in prostate cancer.Asian journal of urology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies have demonstrated that miRNAs have influence on tumorigenesis and progression of human cancers, including invasion and migration. Thus, the role of miR-205/ZEB1 axis for the migration and invasion of prostate cancer cells was explored in the present study. The miR-205-5p and zinc finger E-box binding homeobox 1 (ZEB1) mRNA expression levels were observed in prostate cancer tissues or cell lines via reverse transcription-quantitative PCR (RT-qPCR), and the protein level of ZEB1 was measured by western blotting. Dual-Luciferase Reporter Assay was used to verify the relationship between miR-205-5p and ZEB1. In addition, cell migration and invasion was measured by Transwell assay. The results revealed that, compared with the control, downregulation of miR-205-5p was detected in prostate cancer tissues and cell lines, and miR-205-5p overexpression was found to inhibit cell migration and invasion. Moreover, miR-205-5p was confirmed to directly target ZEB1 in prostate cancer. Importantly, ZEB1 was identified to weaken the inhibitory effect of miR-205-5p in prostate cancer. In conclusion, miR-205-5p inhibited cell migration and invasion in prostatic carcinoma by targeting ZEB1 and miR-205-5p/ZEB1 axis shows potential to be developed in therapeutic strategies for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.